JP2013533239A - 増殖性疾患の治療に有用なβカルボリン誘導体 - Google Patents

増殖性疾患の治療に有用なβカルボリン誘導体 Download PDF

Info

Publication number
JP2013533239A
JP2013533239A JP2013515921A JP2013515921A JP2013533239A JP 2013533239 A JP2013533239 A JP 2013533239A JP 2013515921 A JP2013515921 A JP 2013515921A JP 2013515921 A JP2013515921 A JP 2013515921A JP 2013533239 A JP2013533239 A JP 2013533239A
Authority
JP
Japan
Prior art keywords
alkyl
alkyloxy
halo
hydrogen
alkylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013515921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533239A5 (enExample
Inventor
フレデリック，ラファエル
マセリール，ベルナール
ルニエ，ジェレミー
ウーテル，ジョアン
ブリュイエール，セリーヌ
キス，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Facultes Universitaires Notre Dame de la Paix
Original Assignee
Facultes Universitaires Notre Dame de la Paix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facultes Universitaires Notre Dame de la Paix filed Critical Facultes Universitaires Notre Dame de la Paix
Publication of JP2013533239A publication Critical patent/JP2013533239A/ja
Publication of JP2013533239A5 publication Critical patent/JP2013533239A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013515921A 2010-06-25 2011-06-24 増殖性疾患の治療に有用なβカルボリン誘導体 Pending JP2013533239A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35860910P 2010-06-25 2010-06-25
EP2010059083 2010-06-25
US61/358,609 2010-06-25
EPPCT/EP2010/059083 2010-06-25
PCT/EP2011/060658 WO2011161256A1 (en) 2010-06-25 2011-06-24 Beta carboline derivatives useful in the treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
JP2013533239A true JP2013533239A (ja) 2013-08-22
JP2013533239A5 JP2013533239A5 (enExample) 2014-06-26

Family

ID=44453837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515921A Pending JP2013533239A (ja) 2010-06-25 2011-06-24 増殖性疾患の治療に有用なβカルボリン誘導体

Country Status (5)

Country Link
US (1) US9168247B2 (enExample)
EP (1) EP2585463A1 (enExample)
JP (1) JP2013533239A (enExample)
CA (1) CA2803697A1 (enExample)
WO (1) WO2011161256A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523315A (ja) * 2017-06-09 2020-08-06 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968284B1 (en) 2013-03-14 2021-04-21 Osteoqc Inc. Alkyl-amine harmine derivatives for promoting bone growth
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20160106721A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
CN104530043B (zh) * 2014-12-03 2017-06-06 西北农林科技大学 9‑取代β‑咔啉类化合物及其用于制备预防或治疗肿瘤药物的应用
CN105753860B (zh) * 2014-12-16 2018-03-06 兰州大学 β‑咔啉类生物碱及其在制备抗肿瘤药物中的应用
WO2018119208A1 (en) 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
EP3717475B1 (en) 2017-11-20 2023-06-07 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11903949B2 (en) 2018-08-14 2024-02-20 Ossifi Therapeutics Llc Fluoro beta-carboline compounds
AU2019321434B2 (en) 2018-08-14 2025-05-08 Ossifi Therapeutics Llc Pyrrolo - dipyridine compounds
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CN114644626A (zh) * 2020-12-18 2022-06-21 南京施江医药科技有限公司 一种苯环类化合物及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19807993A1 (de) * 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
JP2003527394A (ja) * 2000-03-15 2003-09-16 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ベーターカルボリン
JP2006526580A (ja) * 2003-06-02 2006-11-24 新疆華世丹薬物研究有限責任公司 ハルミン誘導体、これらの調製において使用する中間体、調製過程およびこれらの使用
CN101139347A (zh) * 2007-10-15 2008-03-12 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
GB2447791A (en) * 2007-03-23 2008-09-24 Univ Dundee Pharmaceutical formulations and compounds for use in alleviating conditions related to Down's syndrome
WO2008157358A1 (en) * 2007-06-15 2008-12-24 University Of Medicine And Dentistry Of New Jersey Methods for treating neoplasia and for identifying compositions useful in such therapy
WO2009047298A2 (en) * 2007-10-12 2009-04-16 Bioalliance Pharma Dimers of harmol or of its derivatives and uses thereof
CN101429198A (zh) * 2007-11-09 2009-05-13 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物及其应用
WO2010015636A1 (en) * 2008-08-06 2010-02-11 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19807993A1 (de) * 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
JP2003527394A (ja) * 2000-03-15 2003-09-16 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ベーターカルボリン
JP2006526580A (ja) * 2003-06-02 2006-11-24 新疆華世丹薬物研究有限責任公司 ハルミン誘導体、これらの調製において使用する中間体、調製過程およびこれらの使用
GB2447791A (en) * 2007-03-23 2008-09-24 Univ Dundee Pharmaceutical formulations and compounds for use in alleviating conditions related to Down's syndrome
WO2008157358A1 (en) * 2007-06-15 2008-12-24 University Of Medicine And Dentistry Of New Jersey Methods for treating neoplasia and for identifying compositions useful in such therapy
WO2009047298A2 (en) * 2007-10-12 2009-04-16 Bioalliance Pharma Dimers of harmol or of its derivatives and uses thereof
CN101139347A (zh) * 2007-10-15 2008-03-12 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
CN101429198A (zh) * 2007-11-09 2009-05-13 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物及其应用
WO2010015636A1 (en) * 2008-08-06 2010-02-11 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JPN5013007544; ＪＩＮＧ　ＺＨＡＮＧ: 'ＤＨ１６６，　Ａ　ＢＥＴＡ-ＣＡＲＢＯＬＩＮＥ　ＤＥＲＩＶＡＴＩＶＥ，　ＩＮＨＩＢＩＴＳ　ＴＨＥ　ＫＩＮＡＳＥ　ＡＣＴＩＶＩＴＹ　ＯＦ　ＰＬＫ１' ＣＡＮＣＥＲ　ＢＩＯＬＯＧＹ　＆　ＴＨＥＲＡＰＹ Ｖ８　Ｎ２４, 20091215, Ｐ２３７４-２３８３ *
JPN5013007545; ＣＡＯ　Ｒ: 'ＤＥＳＩＧＮ，　ＳＹＮＴＨＥＳＩＳ　ＡＮＤ　３Ｄ-ＱＳＡＲ　ＯＦ　ＢＥＴＡ-ＣＡＲＢＯＬＩＮＥ　ＤＥＲＩＶＡＴＩＶＥＳ　ＡＳ　ＰＯＴＥＮＴ　ＡＮＴＩＴＵＭＯＲ　ＡＧＥＮＴＳ' ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖ４５　Ｎ６, 20100601, Ｐ２５０３-２５１５, ＥＤＩＴＩＯＮＳ　ＳＣＩＥＮＴＩＦＩＱＵＥ　ＥＬＳＥＶＩＥＲ *
JPN5013007546; ＳＯＮＧ　Ｙ: 'ＢＥＴＡ-ＣＡＲＢＯＬＩＮＥＳ　ＡＳ　ＳＰＥＣＩＦＩＣ　ＩＮＨＩＢＩＴＯＲＳ　ＯＦ　ＣＹＣＬＩＮ-ＤＥＰＥＮＤＥＮＴ　ＫＩＮＡＳＥＳ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ Ｖ１２　Ｎ７, 20020408, Ｐ１１２９-１１３２, ＰＥＲＧＡＭＯＮ *
JPN6015012544; Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ　Ｌｅｔｔｅｒｓ ９（２３）, 1999, ｐ．３３１９-３３２４ *
JPN6015012546; Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ ４０（１０）, 2005, ９９１-１００１ *
JPN6015012547; Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ １２（１７）, 2004, ４６１３-４６２３ *
JPN6015012549; Ａｎｎａｌｅｓ　Ｐｈａｒｍａｃｅｕｔｉｑｕｅｓ　Ｆｒａｎｃａｉｓｅｓ ４３（１）, 1985, ８３-８ *
JPN6015012550; Ｊｏｕｒｎａｌ　ｏｆ　Ｎａｔｕｒａｌ　Ｐｒｏｄｕｃｔｓ ６４（１１）, 2001, １４５４-１４５６ *
JPN6015012552; Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ　Ｌｅｔｔｅｒｓ １３（１４）, 2003, ２４１９-２４２２ *
JPN6015012554; Ａｒｃｈｉｖｕｍ　Ｉｍｍｕｎｏｌｏｇｉａｅ　ｅｔ　Ｔｈｅｒａｐｉａｅ　Ｅｘｐｅｒｉｍｅｎｔａｌｉｓ ３４（３）, 1986, ３２３-６ *
JPN6015012555; Ｂｕｌｌｅｔｉｎ　ｏｆ　ｔｈｅ　Ｆａｃｕｌｔｙ　ｏｆ　Ｐｈａｒｍａｃｙ　（Ｃａｉｒｏ　Ｕｎｉｖｅｒｓｉｔｙ） Ｖｏｌｕｍｅ　Ｄａｔｅ　１９７０，　９（１）, 1971, ２２３-９ *
JPN6015012557; Ｎａｔｕｒａｌ　Ｐｒｏｄｕｃｔ　Ｒｅｓｅａｒｃｈ １８（４）, 2004, ３４１-３４７ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523315A (ja) * 2017-06-09 2020-08-06 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物
JP7225125B2 (ja) 2017-06-09 2023-02-20 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物

Also Published As

Publication number Publication date
US20130116273A1 (en) 2013-05-09
WO2011161256A1 (en) 2011-12-29
EP2585463A1 (en) 2013-05-01
US20140005220A9 (en) 2014-01-02
US9168247B2 (en) 2015-10-27
CA2803697A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
JP2013533239A (ja) 増殖性疾患の治療に有用なβカルボリン誘導体
JP6903796B2 (ja) Ｆｇｆｒ４阻害剤としての二環式複素環
JP7505023B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
JP6208223B2 (ja) 新規化合物
JP6911031B2 (ja) 免疫調節剤としての複素環化合物
TWI615393B (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
JP6067725B2 (ja) Ｆｇｆｒキナーゼモジュレーターとしてのキノリン
JP6194046B2 (ja) 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法
JP6806342B2 (ja) インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
KR102738182B1 (ko) 암을 치료하기 위한 Trk 키나제 저해제로서의 5-(2-(2,5-다이플루오로페닐)피롤리딘-1-일)-3-(1H-피라졸-1-일)피라졸로[1,5-a]피리미딘 유도체 및 관련 화합물
WO2018166493A1 (zh) 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2018202202A1 (zh) 具有激酶抑制活性的化合物、其制备方法和用途
CN102816175A (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
CN113164409A (zh) 具有雌激素受体α降解活性的新型化合物及其用途
CN110072865B (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
CN110799505B (zh) 用于治疗癌症、视网膜病症和心肌病的三取代嘧啶化合物和组合物
CN118420620A (zh) 杂环化合物
TW201835079A (zh) ６－吡唑－［１，２，４］三唑並［４，３－α］吡啶－３－醯胺類衍生物、其製備方法及其在醫藥上的應用
CN103313707A (zh) 二苯基-胺衍生物的用途、合成方法及药物组合物
JP6586463B2 (ja) ＰＩ３Ｋβ阻害剤としての複素環連結イミダゾピリダジン誘導体
CN118546161A (zh) 并氮杂环类化合物及其用途
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
RU2827699C1 (ru) Бициклические гетероциклические ингибиторы fgfr4, фармацевтические композиции и составы, содержащие их, и их применение
JP2019509996A (ja) コルチスタチン類縁体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160105